Pfizer is backed by strong H1 results, a promising pipeline, improved financials, and solid valuation with long-term growth ...

Pfizer's stock price is down materially from its 2021 highs, but it is also up notably from its April 2025 lows.

Pfizer faces lawsuits from 1,000 women alleging Depo-Provera birth control caused brain tumours, amid new research showing ...

More than 1,000 women say Pfizer ignored evidence linking Depo-Provera to brain tumors—and used the FDA’s decision to protect itself.

Pfizer is working hard to deal with some big headwinds it has coming up, but in five years, this should all be in the past.

Pfizer enters the obesity drug market with a reasonably valued deal, while valuation remains attractive and technicals show ...

More than a year after Pfizer and venture capital company Flagship Pioneering struck a partnership investing in 10 life sciences programs, the two unveiled a collaboration with Quotient Therapeutics.

Pfizer is doing a little house cleaning of its pipeline, but not to worry. CEO Albert Bourla, Ph.D., is expecting to bring on external science that could help reap "at least $25 billion of ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. (NEXSTAR) – At the urging of the Food and ...

Pfizer Inc., the world's biggest drug maker, will change the label for its Viagra impotence pill to warn doctors about sudden vision loss that has occurred in some men who took the drug. The Food and ...

Pfizer and BioNTech announced Friday plans to add a third dose of the COVID-19 vaccine in an ongoing trial with young children, as the current two-dose regimen didn’t appear to be strong enough for ...

The next wave of genomic medicine is shaping up to include gene-editing therapies that do their work inside the patient, and Pfizer and Bayer each have new alliances that will broaden their reach to ...